Associated Papers
Diosgenin reduces β-sheet content in mutated α-syn aggregation: Insights from conformational dynamics at intracellular and extracellular neuronal salt concentrations.
Nandeshwar et al.
Journal of Molecular Graphics & Modelling, 2026
Multiple system atrophy: advances in pathogenesis and emerging therapeutic strategies.
Chen Z et al.
Journal of Neurology, 2025
Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives.
Pitton Rissardo J et al.
Brain Sciences, 2025
Challenges and Opportunities of Early Parkinson's Disease Biomarkers: α-Synuclein, Leucine-Rich Repeat Kinase 2 (LRRK2), DJ-1, and microRNAs.
Heineman A et al.
Cureus, 2025
The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance.
Lange LM et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Environmental Factors Exacerbate Parkinsonian Phenotypes in an Asian-Specific Knock-In LRRK2 Risk Variant in Mice.
Bichler Z et al.
International Journal of Molecular Sciences, 2025
Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease.
Raza A et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025
The homozygous LRRK2.p.N1437D point mutation mouse is a novel model of parkinsonism.
Gan LH et al.
Npj Parkinson's Disease, 2025
Viral mediated α-synuclein overexpression results in greater transgene levels and α-synuclein overload in mice bearing kinase dead mutation of LRRK2.
Albanese F et al.
Scientific Reports, 2025
LRRK2 G2019S Mutated iPSC-Derived Endothelial Cells Exhibit Increased α-Synuclein, Mitochondrial Impairment, and Altered Inflammatory Responses.
Sonninen TM et al.
International Journal of Molecular Sciences, 2024
Targeting Protein Misfolding and Aggregation as a Therapeutic Perspective in Neurodegenerative Disorders.
Sidoryk-Węgrzynowicz M et al.
International Journal of Molecular Sciences, 2024
Genetic-based diagnostics of Parkinson's disease and other Parkinsonian syndromes.
Somerville EN et al.
Expert Review of Molecular Diagnostics, 2024
Low-dose radiation decreases Lrrk2 levels in the striatum of large mammalian brains: New venues to treat Parkinson's disease?
Iacono D et al.
Parkinsonism & Related Disorders, 2024
Impaired Sonic Hedgehog Responsiveness of Induced Pluripotent Stem Cell-Derived Floor Plate Cells Carrying the LRRK2-I1371V Mutation Contributes to the Ontogenic Origin of Lower Dopaminergic Neuron Yield.
Potdar C et al.
Stem Cells and Development, 2024
Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival.
Kang J et al.
Biorxiv : the Preprint Server for Biology, 2024
Modeling Parkinson's disease in LRRK2 rodents.
Domenicale C et al.
Neuronal Signaling, 2023
Autosomal dominant Parkinson's disease caused by the recently identified LRRK2 N1437D mutation in a Chinese family: Clinical features, imaging findings, and functional impact.
Sun YM et al.
Parkinsonism & Related Disorders, 2023
Genetic Evidence for Endolysosomal Dysfunction in Parkinson's Disease: A Critical Overview.
Yahya V et al.
International Journal of Molecular Sciences, 2023
Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models.
Chin RM et al.
Biorxiv : the Preprint Server for Biology, 2023
Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing.
Jagtap YA et al.
Frontiers in Cell and Developmental Biology, 2023
Effects of Mutations and Post-Translational Modifications on α-Synuclein In Vitro Aggregation.
Pancoe SX et al.
Journal of Molecular Biology, 2022
Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.
Ravinther AI et al.
International Journal of Molecular Sciences, 2022
The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases.
Tsafaras G et al.
Neurobiology of Disease, 2022
The genetic background of Parkinson's disease and novel therapeutic targets.
Salamon A et al.
Expert Opinion on Therapeutic Targets, 2022
Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
Chen ML et al.
Journal of Biomedical Science, 2022
Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.
Thakur G et al.
Genes, 2022
Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson's disease patients.
Stern S et al.
Npj Parkinson's Disease, 2022
LRRK2 and Proteostasis in Parkinson's Disease.
Pérez-Carrión MD et al.
International Journal of Molecular Sciences, 2022
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts.
Petropoulou-Vathi L et al.
Npj Parkinson's Disease, 2022
Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson's disease.
Choudhury SP et al.
Npj Parkinson's Disease, 2022
Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson's disease.
Kozina E et al.
Npj Parkinson's Disease, 2022
Age-related LRRK2 G2019S Mutation Impacts Microglial Dopaminergic Fiber Refinement and Synaptic Pruning Involved in Abnormal Behaviors.
Zhang Q et al.
Journal of Molecular Neuroscience : Mn, 2022
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.
Chang EES et al.
Translational Neurodegeneration, 2022
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
Pang SY et al.
Translational Neurodegeneration, 2022
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.
Novello S et al.
Neurobiology of Disease, 2022
miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease.
Suvarna V et al.
Frontiers in Pharmacology, 2022
LRRK2 along the Golgi and lysosome connection: a jamming situation.
Piccoli G et al.
Biochemical Society Transactions, 2021
The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.
Cresto N et al.
International Journal of Molecular Sciences, 2021
LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
Van der Perren A et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics, 2021
Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism.
Chittoor-Vinod VG et al.
International Journal of Molecular Sciences, 2021
DNA damage and repair in Parkinson's disease: Recent advances and new opportunities.
Gonzalez-Hunt CP et al.
Journal of Neuroscience Research, 2021
Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM et al.
Journal of Parkinson's Disease, 2021
Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models.
Abe T et al.
Frontiers in Neurology, 2021
Single-Cell Transcriptomics of Parkinson's Disease Human In Vitro Models Reveals Dopamine Neuron-Specific Stress Responses.
Fernandes HJR et al.
Cell Reports, 2020
Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinson's disease.
Zhou ZD et al.
Ageing Research Reviews, 2020
The Parkinson's disease-associated kinase LRRK2 regulates genes required for cell adhesion, polarization, and chemotaxis in activated murine macrophages.
Levy DR et al.
The Journal of Biological Chemistry, 2020